AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Marketbeat

Published November 3, 2026 · Updated November 4, 2026

Cybin (NASDAQ: HELP) Stock Price Down 6.6% - Here's What Happened - MarketBeat

Read the full story at Marketbeat

psychedelic-based treatments for mental health conditions. ... Analysts Set New Price Targets. Magic Mushrooms , Hard Cash: Compass Pathways' Trial Win,.

Post on X

Share this story

Surfaced by this Google Alert

Magic mushrooms